Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
Chris VanDeusen, PhD
Advertisement
Chris VanDeusen, PhD, is the Chief Scientific Officer of Artax Biopharma.
Articles by Chris VanDeusen, PhD
Advertisement
Latest Updated Articles
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in PsoriasisPublished: May 15th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
